Ivermectin and Fenbendazole for Female Reproductive System: 19 Case Reports (2025)

Introduction

Cancers of the female reproductive system, including ovarian, endometrial (uterine), and cervical cancers, represent a significant global health burden, often presenting at advanced stages with limited treatment options and poor prognosis. Conventional therapies such as chemotherapy, radiation, and surgery, while effective in some cases, frequently fail in recurrent or metastatic disease, prompting exploration of drug repurposing strategies. 

This compilation examines emerging case reports on the off-label use of antiparasitic agents—primarily ivermectin and fenbendazole, alongside related benzimidazoles like mebendazole—in managing these malignancies. Drawing from 19 documented cases, the article categorizes outcomes by cancer type and integrates mechanistic insights from preclinical studies, where these compounds have demonstrated antitumor effects such as microtubule disruption, inhibition of oncogenic signaling pathways (e.g., PAK1, Wnt/β-catenin), induction of apoptosis, and potential synergy with standard treatments. While the evidence remains preliminary and largely anecdotal, these reports highlight potential adjunctive roles for repurposed drugs in challenging clinical scenarios, underscoring the need for cautious interpretation and further investigation.

Note: The case reports below provide detailed, practical information on fenbendazole, ivermectin, and cancer that both patients and clinicians may find useful and actionable. They are categorized by cervical, uterine (endometrial), and ovarian cancer.

1. Cervical Cancer Success Stories (2 cases)

Case 2: SCNECC (Small Cell Neuro-Endocrine Carcinoma of the Cervix)

@dori61318179 shared on X in May 2025 (source):

"Our daughter was diagnosed with SCNECC And was told she had 30% chance to live three years with traditional treatment. We immediately started her on your protocol, and after only four months, she is completely cancer free! God bless you, sir!"

Case 1: 50s year old Stage 4 Cervical Cancer patient (October 2024 and November 2024 Update)

November 2024 - Case study from Dr William Makis (X/Twitter):

IVERMECTIN & FENBENDAZOLE Testimonial - 50s year old Stage 4 Cervical Cancer patient - CA125 drops 46% in 2 months on high dose protocol! 

50s year old Stage 4 Cervical Cancer metastatic to liver patient (USA) 

We started a Protocol early Sep.2024: Ivermectin 2mg/kg/day (split over 2 doses) Fenbendazole 2000mg/day (split over 2 doses) Continue ongoing Tivdak (Tisotumab vedotin) (there was no improvement in CA125 on it so far) 

(we switched Fenbendazole brands after a few weeks, when CA125 hit 99.1) Results: 46% drop in CA125 in 1.5 months ! 

The picture of the CA125 trend is worth a thousand words!

October 2024 - Case study from Dr William Makis (X/Twitter):

IVERMECTIN & FENBENDAZOLE TESTIMONIAL - Stage 4 Cervical Cancer patient sees first dramatic drop in blood cancer markers after a few weeks of adjusting Ivermectin & Fenbendazole doses!

We started a High Dose Ivermectin/Fenbendazole Protocol beginning of September and after 4 weeks the CA125 value hadn’t changed, it had gone from 91U/mL to 99.2U/mL which I considered stable but a little bit stubborn. 

We were a bit slow getting the Ivermectin up, so I increased it by 30% increments to +100%.

We also switched up and mixed the Fenbendazole Brands! And the next CA125 dropped by 30% for the first time! 

In just 3 weeks! You have to be able to adapt and fine-tune. Ivermectin really does work at higher doses. But sometimes it’s not easy to get there. And for Fenbendazole, you CANNOT be married to a brand. Mix things up. If you feel a brand is not working, add a completely different brand! DON’T BE AFRAID TO CHANGE BRANDS! That’s the lesson here. Be flexible.

"Switched from Happy Healing to Sanare Lab Fenbendazole"

2. Endometrial (Uterine) Cancer (7 cases)

Uterine cancer, also known as womb cancer, includes two types of cancer that develop from the tissues of the uterus. Endometrial cancer forms from the lining of the uterus, and uterine sarcoma forms from the muscles or support tissue of the uterus.

Case 7: 68 year old Ontario woman with Stage 3 Endometrial Cancer

Dr. William Makis shared on X.com in November 2025:

IVERMECTIN and FENBENDAZOLE Testimonial - 68 year old Ontario woman with Stage 3 Endometrial Cancer awaits surgery for 2 months...the surgeon was shocked! 

What's better than a shocked Oncologist? A shocked Surgeon!! 

Full disclosure: I've already done this to a bunch of surgeons...and each time is better than the last!

STORY 68 year old Ontario woman with Stage 3 Endometrial Cancer awaits surgery for 2 months. 

She takes: 

• Ivermectin 1mg/kg/day 
• Fenbendazole 1332mg/day 

“To the surgeon’s surprise, no cancer had spread beyond the original tumor” 

“It was clearly your protocol that stopped any spread.” 

This is where cancer treatment history is being made. You can wait for surgery and do nothing. Or you can take Ivermectin, Fenbendazole, Mebendazole and either shrink your tumor or prevent your tumor from spreading! This is early on - when there’s been no chemo, no radiation, no immunotherapy. No damage to the immune system.

Cases 3 - 6: Endometrial (Uterine) cancer

Dr. William Makis shared on X (Twitter) in March 2025:

IVERMECTIN and FENBENDAZOLE Testimonials - ENDOMETRIAL Cancer - Four patients from Canada, USA and Germany respond. This is also a world's first!  I had a pile of good responses from my Endometrial Cancer patients so I thought it would make sense to put some together for a short article. Summary: I have seen Stage 4 Endometrial cancers respond to both Ivermectin and Fenbendazole.  In this article I present four cases: Case 01: 88 yr old Female (Germany) Stage 4 Endometrial Ca, on Fenben CA19-9 dropped from 800 to 90, added Ivermectin and CA19-9 dropped to 80. That’s 90% decrease in CA19-9 Cancer marker. Case 02: 83 yr old Female (Canada) High Grade Serous Endometrial Ca Stage 4, on Ivermectin 1mg/kg/day and Fenben 888mg/day, omental metastasis decreased in size after 2 months. Case 03: 63 yr old Female (USA) High Grade Serous Endometrial Cancer, had surgery in Sep.2024, on Ivermectin 1mg/kg/day and Fenbendazole 888mg/day, “Cancer Free” with negative PET/CT in Jan.2025 after 5 months.

Case 04: 74 yr old Female (Canada) Stage 4 Endometrial Ca, CA125 dropped from 659 to 68 to 44, after 3 months.

The use of Ivermectin and Fenbendazole in Endometrial Cancer has never been published, so my Ivermectin Cancer Clinic is breaking new ground here.

There is one paper that describes Ivermectin inhibiting the WNT pathway, which is key in the proliferation and growth of certain cancers including ENDOMETRIAL. 2014 Melotti et al: The river blindness drug Ivermectin and related macrocyclic lactones inhibit WNT-TCF pathway responses in human cancer. "A variety of sporadic human cancers have been found to harbor hyperactive canonical WNT signaling" "Other cancers also show an active canonical WNT pathway; these include carcinomas of the lung, stomach, cervix, endometrium, and lung as well as melanomas and gliomas"

"We report that Ivermectin inhibits the expression of WNT‐TCF targets" "Ivermectin inhibits the proliferation and increases apoptosis of various human cancer types" "In vivo, Ivermectin selectively inhibits TCF‐dependent, but not TCF‐independent, xenograft growth without obvious side effects" "Given that Ivermectin is a safe anti‐parasitic agent used by > 200 million people against river blindness, our results suggest its additional use as a therapeutic WNT‐TCF pathway response blocker to treat WNT‐TCF‐dependent diseases including multiple cancers." This is why I can often succeed where the top Cancer Centers in the United States fail. Oncologists don't look at Ivermectin research. In fact, they do everything to avoid it. It's not that they don't know. They don't want to know. Yes, some of this Ivermectin research is obscure, not easy to find, and not easy to read. But it's there. Endometrial cancer responds to Ivermectin, and we have an idea why (Ivermectin blocks a key cancer proliferation pathway called the WNT pathway that is active in Endometrial and Cervical cancers).

Case 2: 81-yr-old female with recurrent Endometrial Uterine Cancer (May, 2023)

My 81 yo mother, Virginia, found out she had recurrent Endometrial Uterine Cancer back in Sept 2022. Stage 4 and Mets to abdominal area, lymph nodes, chest cavity and lungs. Radiation was not an option and she opted out of chemo, which would have only bought her a few extra months but would have made her very sick and weak. The doctor put her on a Hormone Blocker to keep it from growing any more. (But if in the lymph nodes, does it really stop it??) The Dr. sent her home to be under Hospice care for the remainder of her short time left on this earth.

I was not ready to accept this!! (Plus, my father has dementia and desperately needs her!) I prayed to God to give us wisdom and guidance. Within 24 hrs., three people approached me about the Joe Tippen Protocol, which I had never heard of at that time. I figured I might ought to listen so I googled and got sucked in! I started learning everything I could learn about it. Then I presented it to mom. She said, “Well, what do we have to lose!?!?”

So, in Oct, through prayer and God’s guidance, I got her up and running on “things” (FenBen, Tudca, Serrapetase, Tumeric, High-Dose Melatonin, Turkey Tail, Apricot Seeds, drinking Baking Soda water, and rubbing on Frankincense). She has been very weak this whole time so we weren’t sure if it was working or not. We planned her funeral, etc….

Then, 5 mo later, her Dr insisted she have another scan. She was very apprehensive but agreed. We (including the dr) were blown away by the results!!! The tumors are either gone or have shrunk considerably!!!! (All but ONE, which basically has stayed the same). All of the ascites (malignant fluid all in her Ab area) was GONE!! The Doctor patted himself on the back but WE PRAISE GOD AND FENBEN!!!

We take one day at a time and hope and pray for the best for years to come but, for today, things are going well!!! (Other than her weakness)

*UPDATE: I added her protocol as a picture so take notice for those interested.





Case 1: Stage 4 Endometrial carcinoma (January, 2023)

Condition: Endometrial carcinoma

In May 2021 I was diagnosed with stage IV endometrial carcinoma. I went through 6 months of hard chemo and 12 months of Maintenance chemo. March 2022 I started fenbendazole working up to 2000 mg a day, along with other supplements. I had a consult this month with Zahara, and she recommended tweaking a few things and adding a few more supplements. I worked hard on my mindset and made sure I surrounded myself with positivity. I received the best news today I could hope for. No evidence of active disease. Never give up!

Related: Nivolumab and Ipilimumab (Immunotherapies) Combination Treatment in Advanced Ovarian and Endometrial Clear Cell Cancers

3. Ovarian Cancer Success Stories (10 Cases)

This compilation features several case reports involving the use of ivermectin and fenbendazole or mebendazole (benzimidazole) for ovarian cancer and related structure such as fallopian tube cancer.

Case 10 - 2025: 79 year old woman in France with Stage 4 Ovarian Cancer

Dr William Makis shared on X.com in December 2025:

IVERMECTIN, MEBENDAZOLE, Vitamin B17, Graviola (Soursop) Testimonial - 79 year old woman in France with Stage 4 Ovarian Cancer achieves an impossible remission in 2 months!

"Dear Dr.Makis, I am writing to share some excellent news regarding the improvement of my mother's Stage 4 Ovarian Cancer over the past four months" Thus begins an email from the son of a 79 year old Stage 4 Ovarian Cancer patient in France. I've included the entire cancer journey here, which begins with a diagnosis of Stage 4 Ovarian Cancer in Dec.2024 and reaches "complete metabolic regression in Sep.2025. "The Radiologist told her that she no longer sees any cancer metabolic activity on the scans" "Her oncologic surgeon, who has always supported and encouraged her, told my mother that he had never seen results like this." "He even presented her case at a patient follow-up committee meeting with other Oncologist colleagues".

Case 9 - 2025: 54 year old woman from Victoria, AUSTRALIA with Stage 4 Ovarian Cancer

Dr William Makis shared on X.com in December 2025:

IVERMECTIN and FENBENDAZOLE Testimonial - 54 year old woman from Victoria, AUSTRALIA with Stage 4 Ovarian Cancer reports after 7 months - almost in remission!

Another success story from Australia! 

54 year old woman from Victoria, AUSTRALIA with Stage 4 Ovarian Cancer metastatic to lymph nodes.

In May 2025 she started: Ivermectin 1mg/kg/day Fenbendazole 1000mg/day Results after 7 months: “probably complete metabolic response to treatment” "wish to give you a huge thank you! Without you my mother in law probably would not be here" Stage 4 Ovarian Cancer is another one of these cancers that I believe is "curable". I will make sure we get a Clinical Trial on this one because Oncologists have NO SOLUTIONS for Stage 4 Ovarian cancer as patients often become completely resistant to chemotherapy (Ivermectin reverses this chemoresistance!)

Case 8 - 2025: 50 year old woman in ENGLAND with newly diagnosed Stage 4 Ovarian Cancer

Dr William Makis shared on X.com in December 2025:

IVERMECTIN and MEBENDAZOLE Testimonial - 50 year old woman in ENGLAND with newly diagnosed Stage 4 Ovarian Cancer reports after 4 months - is now a surgical candidate!

All three success stories today are International. STORY: 50 year old woman in ENGLAND with newly diagnosed Stage 4 Ovarian Cancer For 4 months she took:

• Ivermectin 1mg/kg/day
• Mebendazole 1500mg/day
• Chemo

Results:

• CA125 dropped 3400 to 38
• Significant tumor shrinkage

"My oncologist has now offered to consider keyhole surgery in February after my six cycles of chemo, due to the tumour shrinkage and how well I have responded" It’s much harder to get Ivermectin or Mebendazole in England and even harder in Europe. What I often see with combination treatments is a game changer in the patient’s entire Cancer Treatment journey - going from not being a surgical candidate, to being a surgical candidate. Because if the Oncologist misses that opportunity with chemo alone, and there isn’t enough tumor shrinkage, that window of opportunity is gone.

Case 7 - 2025: 63 year old Maryland woman with Stage 2 Fallopian Tube Cancer

Dr William Makis shared on X.com in November 2025:

IVERMECTIN and FENBENDAZOLE Testimonial - 63 year old Maryland woman with Stage 2 Fallopian Tube Cancer reports after 1 year!

I love this story! We are now getting into the long term follow-ups... This woman had two surgeries, and took Ivermectin and Fenbendazole between surgeries. Surgery #1 showed cancer cells in peritoneal wash Surgery #2 done 3 weeks later showed NO cancer cells. "The board was shocked" She's been on Ivermectin 1mg/kg/day and Fenbendazole 1332mg/day for almost a year now. "My hematologist ordered my recent CT scan which showed no evidence of recurrence. I'm thrilled!!" "My oncologist does not believe in Ivermectin or Fenbendazole but my hematologist does and said to continue".

Case 6 - 2025: 60s year old woman from Boston with Stage 4 Ovarian Cancer

Dr William Makis shared on X/Twitter in September 2025:

IVERMECTIN and MEBENDAZOLE Testimonial - 60s year old woman from Boston with Stage 4 Ovarian Cancer reports after 3 months Now here's an interesting story! 60s year old woman from Boston with Stage 4 Ovarian Cancer In late Feb, 2025 she started:

• Ivermectin (high dose) 
• Mebendazole (high dose)

Results after 3 months: Metastatic lymph nodes were necrotic. I see this often. After several months of Ivermectin and Mebendazole, when the surgeons go in, they find dead tumors or dead cancer cells. "The cancer cells within the enlarged lymph node which the doctor removed were dead" I'm going to have more stories like this, of unexpected surgical findings after several months of Ivermectin and Fenbendazole or Mebendazole.

Case 5 - 2025: 67 year old WA woman diagnosed with Stage 4 Ovarian Cancer

Dr William Makis shared on X/Twitter in June 2025:

IVERMECTIN and FENBENDAZOLE Testimonial - 67 year old WA woman diagnosed with Stage 4 Ovarian Cancer almost cancer free after 2 months! Another Stage 4 Ovarian Cancer Success Story 67 year old WA woman diagnosed with Stage 4 Ovarian Cancer She started low dose Ivermectin and Fenbendazole in January 2025. By end of February 2025, her CA125 rose from 3000 to over 7000. In mid March 2025 we started: Ivermectin 1.5mg/kg/day Fenbendazole 1500mg/day RESULTS after 2 months: "Your customized protocol, combined with metronomic weekly dosing of paclitaxel and carboplatin and some additional naturopathic anticancer treatments, dropped my cancer markers from a high of over 7000 prior to starting your protocol and weekly chemo in early March to a low of 27 on May 12. "A PET/CT scan on 5/12/25 showed NO METASTASIS found and two small areas of increased uptake." "Thank you for giving me my life back!!!! " "I'm no longer spending much of my time in bed and I'm able to walk my dog for an hour! There's no way chemo alone could have done that." My Take… Ivermectin + Fenbendazole + Chemo is a very powerful combination. Some patients want to avoid chemo and I completely understand. But by the time you’re dealing with Stage 4 Cancer, you usually have to throw everything at it.

Case No. 4: 41-year-old Thai female patient diagnosed with recurrent platinum-resistant clear-cell ovarian cancer (PRCCC) in the year 2020

In this case report, we present the case of a 41-year-old Thai female patient diagnosed with recurrent platinum-resistant clear-cell ovarian cancer (PRCCC) in the year 2020. After undergoing chemotherapy for two courses and failing to respond to treatment, she began alternative medicine with repurposing drugs in November 2020. Simvastatin, metformin, niclosamide, mebendazole, itraconazole, loratadine, and chloroquine were also administered. Two months after therapy, a computerized tomography (CT) scan revealed a conflict between a decline in tumor marker levels (CA 125, CA 19-9) and an increase in the number of lymph nodes. However, after continuing all medications for 4 months, the CA 125 level decreased from 303.6 to 54 U/ml, and the CA 19-9 level decreased from 1210.3 to 386.10 U/ml. The patient's EQ-5D-5L score increased from 0.631 to 0.829 (abdominal pain and depression), indicating improved quality of life. Overall survival was 8.5 months, and progression-free survival was 2 months.

Source: Repurposing Drugs in Controlling Recurrent Platinum-Resistant Clear-Cell Ovarian Cancer (Case Rep Oncol Med. 2023)

Case 3 - 2025: 63 year old woman with Stage 4 Ovarian Cancer metastatic to peritoneum (April 2025)

Dr William Makis shared on X/Twitter:

IVERMECTIN and MEBENDAZOLE Testimonial - 63 year old woman with Stage 4 Ovarian Cancer metastatic to peritoneum sees CA125 drop from 2138 to 357, most cancer gone on PET! Beware of inexperienced Integrative MDs who want to play with Ivermectin and Fenbendazole! 

This is a success story that almost wasn't.

63 year old woman with Stage 4 Ovarian Cancer metastatic to peritoneum. In early October 2024, she saw an integrative MD who put her on low dose Ivermectin (24mg) and Fenbendazole 300-600mg, eventually increasing to 1000mg a day. Her CA125 increased from 1097 to 1668 (+ Fenben/IVM) to 2628.5 by mid Nov.2024!

Her CA125 rose from 1668 to 2628 after being on Fenbendazole and low dose Ivermectin for over a month! Then she came to me. 

I switched her from 1000mg Fenbendazole to 1000mg Mebendazole and increased the Ivermectin from 24mg to 72mg. Her CA125 from that point onwards: 2628.5 to 853 to 619 to 357 (!!) PET/CT Scan done March 11, 2025 showed:

“extensive peritoneal carcinomatosis seen previously is essentially resolved” “retroperitoneal adenopathy seen previously has returned to normal”
“left axillary adenopathy seen previously has resolved on both CT and PET images” “most of the pelvic adenopathy seen previously has returned to normal on CT and PET”
“suspected capsular implant seen previously at the posterior aspect of the spleen is no longer visible on CT or PET”

Lesson:

Most Integrative MDs don’t know what they’re doing when it comes to Ivermectin and Benzimidazoles. They get the dosing and combinations wrong. This patient wasn’t responding to low doses of Ivermectin or Fenbendazole and the Integrative MD increased the Fenbendazole dose to 1000mg, but the CA125 rose regardless, from 1097 to 2628!

Ovarian Cancer is known to respond to Mebendazole and Ivermectin but South Korean researchers discovered it doesn’t respond well to Fenbendazole. Some health professionals are attracted to the promise of repurposed drugs but wouldn’t know what to do at the sign of first trouble with their Protocol. Imagine coming to a health professional who has no idea what to do when their Ivermectin Protocol fails. You wouldn't go to an inexperienced hairdresser, barber, or car mechanic, for an important job. And what's more important than Stage 4 Cancer?

Case 2: 40s-year-old Stage 4 Ovarian Cancer (Dec 2024)

According to Dr William Makis (X/Twitter):

IVERMECTIN & FENBEDAZOLE Testimonial - 40s year old Stage 4 Ovarian Cancer patient declared "CANCER FREE" after 2 months 40s year old Stage 4 Ovarian Cancer patient followed at a large US Cancer Centre (Mayo Clinic), reached out to me in July 2024 Patient was diagnosed in Feb.2024 with Stage 4 Ovarian Cancer (High Grade Serous Carcinoma) She had 4 cycles of neoadjuvant chemo, then cytoreduction (surgery) June 24, then plan was for 2 additional cycles of chemo. Post Surgery Cancer Clinic Visit in July 2024: plan was for 2 more chemo cycles - patient then reached out to me after her visit. CA125 on July 15, 2024 peaked at 86.7 (pre-surgery it was 41.7) Even though much of the tumor was removed, the CA125 had jumped from 41.7 to 86.7, indicating rapid cancer growth and spread IVERMECTIN: We started a medium dose Protocol:

• Ivermectin 1mg/kg/day
• Fenbendazole 444mg/day
• Melatonin 100+mg/day

6th cycle of chemo 

Two months later she was CANCER FREE.

Do you think the Chemo did it? The same chemo that after 4 cycles resulted in a CA125 of 41.7? And then rapid progression right after surgery? I don’t think so. It was the combination of chemo + IVERMECTIN Protocol. Now, as of Dec.21, with a CA125 of 16 (in the normal range), she’s been CANCER FREE since end of September.

Case 1: October 2024

According to Dr William Makis (X/Twitter):

IVERMECTIN and MEBENDAZOLE Testimonial in a patient with Advanced Ovarian Cancer. 

3 weeks of high dose regimen results in CA125 cancer marker drop of 30%! 

Ovarian cancer is very responsive to Ivermectin but people forget about Mebendazole (FDA approved version of Fenbendazole). (Hint: combine them) 

We hit this cancer hard and have it on the run 3 weeks in!

  

Note: Although technically mebendazole is not the same as fenbendazole, both mebendazole and fenbendazole are part of a larger group of drugs known as benzimidazole*, which are anthelmintic drugs (i.e., drugs that kill parasitic worms). 

*The class of drugs known as benzimidazoles includes fenbendazole, mebendazole, albendazole and flubendazole. 

Fenbendazole and mebendazole are similar in that they both eliminate parasitic worms, but there is a difference. Mebendazole is approved for human consumption by the FDA, while fenbendazole is only approved for veterinary use and has not been approved for human use.

Mebendazole is the form that is approved for human use while fenbendazole is approved for veterinary use. The main difference is the cost. Mebendazole is expensive ~$450 per pill (two pills of mebendazole cost just $4 in the UK.), while fenbendazole is inexpensive ~48 cents per 222 mg free powder dose (Williams, 2019). Albendazole is the form used to treat intestinal parasites in India and these cost 2 cents per pill. 

While most of the pre-clinical research uses mebendazole, probably because it is the FDA-approved-for-humans form of fenbendazole, virtually most of the self-treating clinical reports involve the use of fenbendazole.

Related: Nivolumab and Ipilimumab (Immunotherapies) Combination Treatment in Advanced Ovarian and Endometrial Clear Cell Cancers (JAMA)

Conclusion and Key Takeaway

The case reports compiled here illustrate intriguing outcomes with ivermectin and fenbendazole in advanced female reproductive cancers, including marked reductions in tumor markers (e.g., CA125), prevention of metastasis, achievement of surgical candidacy, and instances of remission in otherwise refractory cases. Preclinical data support plausible mechanisms, such as ivermectin's inhibition of proliferation and migration in ovarian and cervical cell lines, and benzimidazoles' interference with microtubule dynamics and glycolysis. However, these findings are derived from uncontrolled case reports, which are susceptible to reporting bias, placebo effects, and confounding factors, and do not constitute high-level evidence. No randomized controlled trials currently validate efficacy or long-term safety in humans for oncologic indications, and mainstream oncology guidelines do not recommend these agents outside clinical studies due to insufficient data.

Patients facing limited options may find these reports encouraging, but self-medication carries risks, including potential drug interactions and unknown effects on fertility or pregnancy (where animal studies suggest caution). Rigorous, well-designed clinical trials are essential to evaluate dosing, combinations, and outcomes objectively. Until such evidence emerges, decisions regarding repurposed antiparasitics should involve multidisciplinary oncology consultation, with emphasis on established therapies and enrollment in trials where possible. This evolving field warrants continued monitoring as new data may refine our understanding of these compounds' role in integrative cancer care.

Disclaimers:

• Statements on this website have not been evaluated by the Food and Drug Administration. The contents of this website is for educational and informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis or treatment.
• Please do not consider this guide as personal medical advice, but as a recommendation for use by professional providers. Consult with your doctor and discuss with her/him. Our aim here isn't to replace your doctors' advice. It is intended as a sharing of knowledge and information. Do take note that cancer is a continuous struggle between the immune system and the cancer cells. Cancer treatments are meant to assist the immune system in this battle. Any potential treatment—whether conventional or complementary—must be evaluated on a case-by-case basis, with careful consideration of the benefit-risk ratio to ensure both safety and effectiveness.
• The case reports presented reflect the real-life experiences and opinions of other readers or users of the website. The experiences of those readers or users are personal to those particular readers/users and may not necessarily be representative of all readers/users. We do not claim, and you should not assume, that all other readers/users will have the same experiences. Do you own research, consult with relevant medical professionals before attempting to self-treat for any condition.
• Cancer treatment should be part of a multi-modal approach in order to provide the best possible outcome. Diet and lifestyle changes are meant to run alongside conventional treatment. They are complementary, not alternative. 
• Cancer care is a team effort with the patient at the centre. Care should be supervised and coordinated by a primary healthcare provider. Patients with cancer should consult with their regular oncologist as well as an integrative provider/oncologist, in addition to their primary care provider and the supporting nurses, dieticians and other allied healthcare professionals.
• While the term 'alternative' might imply opposition to conventional oncology, we prefer 'complementary,' 'integrated,' or 'holistic.' These terms better reflect the role of these strategies as part of a personalized value-added menu of strategies, ensuring the most effective and safe solutions for patients.
• Integrating a repurposed drug doesn't mean rejecting modern medicine — It enhances it and offers a more comprehensive approach to wellness and healing. By combining conventional cancer management with root-cause resolution, this model creates a path to sustained recovery and resilience. 

Related: 

1. Fenbendazole and Other Stage 4 Cancer Types: The compilation includes over 250 stage 4 cancer case reports across 17 cancer types. Full details are provided in the following: Stage 4 Cancer Remissions with Fenbendazole, Ivermectin and Mebendazole (December 2025 Edition).
2. Fenbendazole, Ivermectin and Mebendazole Cancer Success Stories: 439 Case Reports Compilation of various stages (stages 1 to 4) of different cancer types (December 2025 Edition)